VYNE — VYNE Therapeutics Inc.

VYNE Therapeutics Q3 2021 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenues: $4.1 million, primarily from product sales of AMZEEQ and ZILXI ($4 million) and royalty revenue ($21 million).
• Net Loss: GAAP net loss of $21.3 million ($0.41 per share); adjusted net loss of $18.9 million ($0.36 per share) after excluding $2.4 million in stock-based compensation.
• Operating Expenses: Adjusted operating expenses were $18.4 million, down $1.9 million from Q2 2021, reflecting cost control efforts.
• Cash Position: Approximately $53 million as of September 30, 2021, expected to fund operations through Q2 2022.

2. Strategic Updates and Business Highlights:

• VYNE is refocusing on developing therapies for immuno-inflammatory diseases, highlighted by the licensing of a Bromodomain and Extra-Terminal (BET) Inhibitor Platform.
• Pipeline Developments:
  • VYN201: A topical BET inhibitor expected to enter clinical trials in 2022, showing promising preclinical results in reducing inflammation and improving skin repair.
  • VYN202: An oral BET inhibitor in collaboration with In4Derm, targeting autoimmune conditions.
  • FMX114: A combination topical treatment for atopic dermatitis, with the first patient enrolled in a Phase 1b/2a trial; top-line results anticipated in early Q1 2022.
• The company is progressing with the planned sale of its topical minocycline franchise, which has garnered significant interest.

3. Forward Guidance and Outlook:

• Anticipates adjusted operating expenses to range between $10 million and $15 million in Q4 2021, excluding a one-time $4 million milestone payment.
• Expected adjusted operating expenses of approximately $10 million per quarter in 2022, contingent on successful trial outcomes.
• Multiple early-stage clinical milestones anticipated over the next 12 to 18 months.

4. Bad News, Challenges, or Points of Concern:

• The company reported a substantial net loss, raising concerns about financial sustainability without additional revenue streams or successful product launches.
• The ongoing sale of the topical minocycline franchise may indicate a shift in focus but also presents a risk if the sale does not meet expectations or timelines.
• Competitive pressures from established therapies in the immuno-inflammatory space, particularly from JAK inhibitors, pose challenges for VYNE’s new products.

5. Notable Q&A Insights:

• Questions regarding the specific indications for VYN201 and VYN202 highlighted the potential for VYN201 to target mild-to-moderate conditions while VYN202 may address more severe cases.
• The management expressed confidence in the safety and efficacy of FMX114, particularly in light of recent regulatory scrutiny on JAK inhibitors.
• The company has not yet conducted comparative studies of VYN201 against JAK inhibitors but plans to focus on this as they refine their indications.
• The management emphasized the differentiated safety profiles of their BET inhibitors, particularly the selective BD2 approach for VYN202, which may mitigate common side effects seen in other BET inhibitors.

Overall, VYNE Therapeutics is navigating a strategic transition with a focus on innovative therapies for immuno-inflammatory diseases, while managing financial losses and preparing for upcoming clinical milestones.